drugset / Trial / NCT01602822
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
Phase 4
Terminated
11 enrolled
Kenneth H. Mayer, MD
Abbott · collabBristol-Myers Squibb · collabGilead Sciences · collab
NaSingle-groupOpen-labelPrevention
Summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-05
- Completion
- 2012-05
Outcome
Outcome not reported
Stopped: “Grade 3 elevation in liver function tests”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 300 mg | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |